BlueFactory is a real innovation pool, attracting entrepreneurs and scientists in life science alike. Founded in 2020 by a strong multi-disciplinary team exhibiting complementary skills in different fields, ELIONOVA is revolutionizing the rapid testing market, offering an innovative diagnostic platform and in vitro diagnostic products for human and animal health.
Coming from the world of Pharma, biotech and med-tech, ELIONOVA has 8 employees, including experts who made their mark in the field of rapid tests during the mad cow epidemic in the 1990s. The COVID-19 epidemic has highlighted the need for rapid and precise diagnostics which will be delivered by Elionova’s products.
The ELIONOVA’S device
Until ELIONOVA’s innovative solution came to market, lateral flow tests were either quantitative and reliable but time consuming and expensive, or fast yet semi quantitative. By developing their EVA (EVANESCENCE Biosensor Technology) technology, the researchers from the Fribourg spin-off have managed to combine precision, simplicity and speed, without compromise, allowing them to deliver reliable diagnoses within 5 to 10 minutes.
EVA – Evanescence Biosensor Technology
This optical and immunological technology is technically similar to common ELISA technology, which is broadly used in standard diagnostic laboratories and whose results are reliable but time consuming and complicated involving may steps. The EVA consumable test is a one step procedure as the device already contains all test-specific reagents. Simply add the sample test into plastic device, place it in the reader and measure. The fluorophors bound at the bottom of the test well are generating a signal which can be read in real time, hence the 5-10 minutes assay time providing quantitative results for many applications such as pathogen detection.
ELIONOVA’s upcoming projects
This innovative, easy-to-handle and portable technology, which can be used in any healthcare setting, is revolutionizing a medical environment that had a tendency to give up on certain complicated, unreliable or particularly expensive diagnoses. ELIONOVA is now working on EVA tests to test platelet donors and recipients to ensure the success of a platelet transfusion, or to detect the level of protective antibodies in the body of a patient who is reluctant to be (re-)vaccinated against COVID-19. In essence, Elionova’s solution is an innovative alternative offering a cheaper and more rapid solution for the diagnostic market.